
Danish medtech firm Nanovi, whose chair of the board is Ambu heir Simon Hesse Hoffmann, has reached one of the bigger milestones in its history, which began in 2012 when the company was spun out from the Technical University of Denmark, DTU.
On Monday, the company announced it has submitted Bioxmark, a novel liquid soft tissue marker designed to be used in radiation therapy (RT) for multiple cancer types, for approval with the US Food and Drug Administration (FDA).
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app